World's Best Scientists 2026 revealed!
Peter Hohenberger

Peter Hohenberger

D-Index & Metrics

Medicine

D-Index
85
Citations
33995
World Ranking
14431
National Ranking
765

Overview

Peter Hohenberger is affiliated with Heidelberg University in Germany and has contributed extensively to the field of medical research, primarily focusing on oncology and related disciplines. Their scholarly work spans various topics including sarcoma diagnosis and treatment, gastrointestinal tumor research, and vascular tumors.

Their recent papers encompass significant clinical guidelines and research findings, including:

  • Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Sarcoma classification by DNA methylation profiling, 2021, Nature Communications
  • Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients, 2020, European Journal of Cancer
  • Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up, 2021, Annals of Oncology

Hohenberger's research is primarily documented in the following publication venues:

  • Annals of Oncology
  • Oncology Research and Treatment
  • Journal of Clinical Oncology
  • Cancers
  • European Journal of Cancer

Their main fields of study include Medicine, with significant contributions to several specialized subfields such as pulmonary and respiratory medicine, oncology, surgery, gastroenterology, and pathology and forensic medicine.

Specific areas of focus within their research include:

  • Sarcoma diagnosis and treatment
  • Gastrointestinal tumor research and treatment
  • Vascular tumors and angiosarcomas
  • Gastric cancer management and outcomes
  • Cardiac tumors and thrombi
  • Gastrointestinal disorders and treatments
  • Lymphoma diagnosis and treatment

Peter Hohenberger has collaborated frequently with several co-authors, including Bernd Kasper, Jens Jakob, Peter Reichardt, Dimosthenis Andreou, and Eva Wardelmann, each contributing to multiple joint publications.

Best Publications

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

    Heikki Joensuu;Mikael Eriksson;Kirsten Sundby Hall;Jörg T. Hartmann

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Clinical Experiences with Magnetic Drug Targeting: A Phase I Study with 4′-Epidoxorubicin in 14 Patients with Advanced Solid Tumors

    Andreas Stephan Lübbe;Christian Bergemann;Hanno Riess;Folke Schriever

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group

    Alessandro Gronchi;Dirk C. Strauss;Rosalba Miceli;Sylvie Bonvalot

  • Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors.

    Kevin S. Hughes;Rebecca B. Rosenstein;Sate Songhorabodi;Martin A. Adson

  • Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Paolo G. Casali;Jean-Yves Blay;Alexia Bertuzzi;Stefan Bielack

  • Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;S. Bielack;N. Abecassis;H.T. Aro

  • Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

    Eva Wardelmann;Sabine Merkelbach-Bruse;Katharina Pauls;Nadja Thomas

  • Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials

    Cornelis J A Punt;Marc Buyse;Claus Henning Köhne;Peter Hohenberger

  • Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials

    Piotr Rutkowski;Martine Van Glabbeke;Cathryn J Rankin;Wlodzimierz Ruka

  • NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

    Sylvie Bonvalot;Piotr L Rutkowski;Juliette Thariat;Sébastien Carrère

  • An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

    B Kasper;C Baumgarten;J Garcia;S Bonvalot

  • Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

    Martine Van Glabbeke;Jaap Verweij;Paolo G Casali;Axel Le Cesne

Frequent Co-Authors

Peter M. Schlag
Peter M. Schlag Charité - University Medicine Berlin
Alessandro Gronchi
Alessandro Gronchi University of Milan
Paolo G. Casali
Paolo G. Casali University of Milan
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Piotr Rutkowski
Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Heikki Joensuu
Heikki Joensuu University of Helsinki
Ian Judson
Ian Judson Institute of Cancer Research
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their career opportunities in healthcare, a variety of online degrees offer flexibility and specialized skill building. Aspiring nurse practitioners may consider completing one of the fastest psych np program options, which allow students to quickly enter the growing field of mental health.

Healthcare administration is another high-demand area, and students can gain essential leadership skills through a healthcare administration degree online. For graduate-level studies, exploring the cheapest online mha programs can help reduce educational costs while advancing your qualifications for management roles.

For nurses pursuing the highest clinical credentials, you might consider the most affordable dnp programs to earn your Doctor of Nursing Practice online. With a wide range of accredited, affordable, and flexible degree pathways, students can find the right fit for their professional goals in the evolving healthcare landscape.

Best Scientists Citing Peter Hohenberger

Trending Scientists

Recently Published Articles